Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
US Army
Teva
McKinsey
Cipla
Baxter
Covington
Express Scripts

Generated: June 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,149,486

« Back to Dashboard

Which drugs does patent 9,149,486 protect, and when does it expire?

Patent 9,149,486 protects CIPRODEX and is included in one NDA.

This patent has eighteen patent family members in sixteen countries.
Summary for Patent: 9,149,486
Title:Method of treating middle ear infections
Abstract: Aqueous suspension formulations containing dexamethasone and ciprofloxacin are disclosed for the treatment of middle ear infections in human patients having an open tympanic membrane.
Inventor(s): Wall; G. Michael (Fort Worth, TX), Conroy; Peter J. (Fort Worth, TX)
Assignee: ALCON PHARMACEUTICALS LTD (CH)
Application Number:14/468,257
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 9,149,486

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis Pharms Corp CIPRODEX ciprofloxacin; dexamethasone SUSPENSION/DROPS;OTIC 021537-001 Jul 18, 2003 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y TREATMENT OF ACUTE OTITIS MEDIA ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,149,486

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,846,650 Method of treating middle ear infections ➤ Try a Free Trial
9,402,805 Method of treating middle ear infections ➤ Try a Free Trial
9,345,714 Method of treating middle ear infections ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 9,149,486

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Denmark 1429780 ➤ Try a Free Trial
European Patent Office 1429780 ➤ Try a Free Trial CA 2012 00045 Denmark ➤ Try a Free Trial
European Patent Office 1429780 ➤ Try a Free Trial 13C0012 France ➤ Try a Free Trial
European Patent Office 1429780 ➤ Try a Free Trial SPC/GB12/058 United Kingdom ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Teva
Merck
Daiichi Sankyo
Cipla
Cerilliant
Accenture
Julphar
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.